Teresa Cole
Family · Manchester, KYNPI 1588073886
Payments from drug & device makers
Across 263 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$861
- Novo Nordisk$747
- Lilly USA, LLC$404
- GSK$339
- AstraZeneca$327
- Merck$284
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,991100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $861 |
| Novo Nordisk | 46 | $747 |
| Lilly USA, LLC | 38 | $404 |
| GSK | 27 | $339 |
| AstraZeneca | 15 | $327 |
| Merck | 16 | $284 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $154 |
| Bayer | 7 | $133 |
| Pfizer | 7 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $86 |
| Dexcom, Inc. | 5 | $85 |
| Phathom Pharmaceuticals, Inc. | 9 | $64 |
| Astellas Pharma US Inc | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Johnson & Johnson | 2 | $45 |
| Ardelyx, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Insulet Corporation | 1 | $27 |
| Shield Therapeutics Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Amgen | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
How this compares
$3,991 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 621 | $179,548 |
| OzempicSemaglutide | 148 | $153,593 |
| JardianceEmpagliflozin | 227 | $150,567 |
| EliquisApixaban | 151 | $104,602 |
| JanuviaSitagliptin Phosphate | 135 | $84,163 |
| MounjaroTirzepatide | 59 | $62,451 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $54,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $52,212 |
| FarxigaDapagliflozin Propanediol | 80 | $49,782 |
| VascepaIcosapent Ethyl | 113 | $39,835 |
| EntrestoSacubitril/Valsartan | 50 | $37,884 |
| LinzessLinaclotide | 49 | $28,172 |
| Spiriva HandihalerTiotropium Bromide | 43 | $22,639 |
| MovantikNaloxegol Oxalate | 45 | $22,355 |
| VraylarCariprazine Hcl | 15 | $21,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Tradjenta | $28 | $177,296280 claims |
| Novo NordiskOzempic, Rybelsus | $747 | $165,013160 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Symbicort | $327 | $123,803223 claims |
| PfizerEliquis | $99 | $104,602151 claims |
| MerckJanuvia | $284 | $84,163135 claims |
| Lilly USA, LLCMounjaro, Trulicity | $404 | $77,05570 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $339 | $74,273124 claims |
| AbbVieLinzess, Vraylar | $861 | $49,49564 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $17,19412 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $5,83313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Manchester
- Eva EdwardsManchester$14K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.